Viskoper J R, Laszt A, Farragi D
Department of Medicine B, Barzilai Medical Center, Ashkelon, Israel.
J Cardiovasc Pharmacol. 1991;18 Suppl 3:S9-11.
The antihypertensive effect of isradipine compared with placebo was assessed in 28 male patients (aged 40-64 years) with mild-to-moderate essential hypertension. After withdrawal of all previous antihypertensive treatment, these patients were entered into a 4-week placebo period followed by randomization to receive double-blind, for 8 weeks, either placebo (n = 14) or isradipine at 1.25-2.5 mg twice daily (n = 14). Twenty-four-hour ambulatory blood pressure was measured by Accutracker at the end of the placebo period and at the end of active treatment. In the isradipine group, both systolic and diastolic blood pressures decreased significantly (p less than 0.0001) whereas blood pressure increased in those taking placebo. In addition, isradipine as monotherapy controlled blood pressure throughout the day and night, and especially during the early morning, in these patients.
在28例年龄40 - 64岁的轻度至中度原发性高血压男性患者中评估了伊拉地平与安慰剂相比的降压效果。在停用所有先前的降压治疗后，这些患者进入为期4周的安慰剂期，随后随机接受双盲治疗，为期8周，其中14例接受安慰剂，14例接受每日两次1.25 - 2.5 mg的伊拉地平。在安慰剂期结束时和积极治疗结束时，使用Accutracker测量24小时动态血压。在伊拉地平组中，收缩压和舒张压均显著降低（p小于0.0001），而服用安慰剂的患者血压升高。此外，在这些患者中，伊拉地平作为单一疗法可在全天和夜间，尤其是清晨控制血压。
